[Infectivity by HIV of different blood products used in Aragon].
In our region, prevalence of anti-HIV antibodies among hemophiliacs B (83.3%) is higher than among hemophiliacs A (47%), as reported in other spanish communities and contrary to other countries, were the opposite phenomenon has been observed. This seems to be due to the volume of hemo-derivatives received, rather than to their different infectivity, as it has been suggested sometimes. In order to assess this infectivity, independently of doses, we have studied two groups of patients, hemophiliacs A transfused with factor III and non-hemophiliacs who had received concentrate of prothrombinic complex factors (CPCF), in doses lower than 10,000 units. Both groups were transfused during the period when seroconversions were observed in our area (1981-1985) and we demonstrated that the difference between their prevalences of anti-HIV antibodies was not statistically significant.
Lucia Cuesta
J F
JF
Servicio de Hematología, Hospital Miguel Servet, Zaragoza.
García Aranda
A
A
D001778:Blood Coagulation Disorders / Q000628:therapy; D001779:Blood Coagulation Factors / Q000009:adverse effects*; D004340:Drug Contamination; D005169:Factor VIII / Q000009:adverse effects*; D015528:HIV Seroprevalence; D006801:Humans
D001779:Blood Coagulation Factors; C025667:prothrombin complex concentrates; D005169:Factor VIII
Infectividad para el VIH de diferentes hemoderivados empleados en Aragón.